Physicochemical and pharmacokinetic parameters of SLMP53-1 calculated using SwissADME (1):
meaning that it is more likely to have better oral bioavailability (10 or less rotary titers and a polar surface area, PSA, equal to or fewer than 140 Å 2 with 12 or fewer hydrogen binding donors and acceptors). Finally, it obeyed the Muegge and Egan filters (Table S2 ). The Muegge model is an independent database capable of discriminating between drug and chemical substances similar to drugs. The Egan filter is based on the PSA and the AlogP98v, providing a robust prediction of drug absorption. SLMP53-1 was also evaluated against models that exclude molecules that are likely to fail biological assays. The analysis showed no warnings from Pains Alert. In addition, the Brenk selection model and the Leadlikeness criteria also proved to be non-infringing (Table S3 ). Pharmacokinetic evaluation by SwissADME also estimated that SLMP53-1 has high gastrointestinal absorption, is capable to penetrate the blood brain barrier (BBB), and has an inhibitory function on cytochrome p450 isoenzymes CYP1A2 and CYP2D6 (Table S4) (Table S7 ). (GI; gastro-intestinal absorption, BBB; blood brain barrier, nCYP; Cytochromes, P-gp; P-glycoprotein). 
